FPT Achieves 2024 EcoVadis Platinum Rating for Sustainability Through Its French Subsidiary
12.12.2024 08:24:00 CET | Business Wire | Press release
Global technology corporation FPT recently achieved the EcoVadis Platinum rating through its French subsidiary. This is the highest distinction in the survey conducted by EcoVadis, an international organization that evaluates corporate sustainability activities. The recognition places FPT in the top 1% of companies evaluated worldwide for their commitment to sustainable business practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211227891/en/
(Graphic: Business Wire)
The EcoVadis rating is a comprehensive assessment of a company’s environmental, social, and governance (ESG) practices. It includes a global network of over 130,000 companies of various sizes across 220+ industries and 180+ countries. Sustainability performance is assessed across 21 criteria in four themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.
FPT attained an overall score of 88/100, with impressive ratings of 90/100 for both Labor & Human Rights and Ethics, and 80/100 for the Environment category. This achievement reflects the company’s commitment to all dimensions of environmental policies, efficient corporate governance protocols, robust employee professional development initiatives, and dedication to reducing carbon emissions.
Mdm. Chu Thi Thanh Ha, Chairwoman of FPT Software, FPT Corporation, said: “FPT’s recognition by EcoVadis comes as part of our broader sustainability strategy, which includes embracing technologies, cultivating future-ready talents and driving new values that will last generations. Moving forward, we will continue to prioritize sustainability across all levels of our operations, with ongoing initiatives and investments to integrate sustainable practices into our solutions and services, as well as the work we deliver to our global customers.”
In 2023, FPT received a Silver rating from EcoVadis, further demonstrating its dedication to sustainable and ethical practices. In 2024, the company achieved ISO 45001 certification, the international standard for occupational health and safety, across its twelve campuses and offices in Vietnam, Germany, and France. Additionally, FPT won the Job Creation Award at ESGBusiness Awards 2024 and joined the Pledge 1% movement, reinforcing its dedication to corporate social responsibility and community engagement.
Since entering France in 2008, FPT has solidified its market position and demonstrated its expertise by collaborating with global leaders such as Airbus, La Poste, Air Liquide, Quadient, etc. In 2023, the French subsidiary entered France's top 100 ICT Companies. That same year, the company further strengthened its capabilities by acquiring an 80% stake in French IT consulting firm AOSIS, enhancing its expertise in SAP, Data, Cloud, and smart solutions tailored for the aerospace, aviation, and transportation industries. Looking ahead, FPT aims to be among the Top 50 IT companies in France, targeting to expand its local workforce to over 500 experts and its presence in France and neighbouring Francophone countries.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information about global IT services, please visit https://fptsoftware.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211227891/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom